Watchman Laa denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for watchman laa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue a "Duplicate Therapy" Denial for the Watchman Left Atrial Appendage Closure Device

The Watchman device is an FDA-approved left atrial appendage (LAA) closure implant used in patients with non-valvular atrial fibrillation to reduce stroke risk. A "duplicate therapy" denial from Cigna typically occurs when the plan determines that the patient is already receiving an alternative stroke-prevention strategy — most commonly long-term anticoagulation — and views the Watchman as redundant rather than complementary or as a replacement.

## Why This Denial Is Appealable

Watchman is not simply an "add-on" to anticoagulation; it is indicated specifically for patients in whom long-term anticoagulation is considered unsuitable due to bleeding risk, contraindication, intolerance, or patient preference documented by their physician. If your cardiologist has determined that anticoagulation is not appropriate for this patient, the Watchman is by definition not duplicating an existing therapy — it is replacing one that cannot safely continue. This distinction is the heart of a strong appeal.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline on your denial notice. Cigna must render a decision within the timeframes required by law.
• External review: After final internal denial, escalate to an IRO. You generally have approximately four months from the final internal denial to request external review.
• Expedited review: Request if clinical urgency — such as documented high stroke risk combined with ongoing anticoagulation contraindication — makes standard timelines dangerous.

## Documentation to Gather

1. Anticoagulation unsuitability documentation: Physician notes explicitly documenting why long-term anticoagulation is not appropriate for this patient (bleeding history, fall risk, prior hemorrhagic event, patient-specific factor, or failed anticoagulation trial). 2. Cardiology evaluation: A complete cardiovascular workup supporting the indication for LAA closure as a stroke-prevention strategy. 3. Prescriber medical-necessity letter: The treating electrophysiologist or cardiologist should explain, in writing, that Watchman is being used as an alternative to — not in addition to — anticoagulation, and why that is clinically appropriate for this patient. 4. Relevant society guideline reference: Note the applicable ACC/AHA or HRS guideline organization's position on LAA closure as an alternative to anticoagulation (without quoting specific numbers).

## Criteria-Mapping Structure

Obtain Cigna's coverage policy for the Watchman device. List every criterion. For each criterion relating to anticoagulation suitability, map it directly to the specific chart documentation that addresses it. Make the case explicitly that this is a therapy substitution, not a duplication.